Jeff Aronin: More than Just a Man

Ever since completing his undergraduate degree in Northern Illinois and an MBA from the DePaul University, Jeff Aronin had his entire career revolve around healthcare and helping people better their lives through attaining appropriate medical attention. Jeff Aronin’s passion and core beliefs drove him to join and become part of the healthcare community responsible for the creation of medicine around the globe. In 2000, Jeff Aronin created Ovation Pharmaceuticals LLC, where he was the CEO. The creation of Ovation Pharmaceuticals LLC was because he felt the need to assist people suffering from neglected or rare diseases to obtain services for their unmet medical requirements.

 

Genuine Goal

The creation of the Ovation Pharmaceuticals LLC helped Jeff Aronin put together his resources to achieve one goal. The goal was to focus on drug development and patients. However, in 2009, he sold the company but still went on to be CEO of the company. The success he had with Ovation Pharmaceuticals LLC lead him to be the CEO and founder of Paragon Biosciences Company. Paragon Biosciences is an investor and incubator company that focuses on the identification of unmet medical requirements. They then build companies with talent to help supply the world with medication.

 

Building Companies

Some of the companies Paragon Biosciences has helped build include the following: Harmony Biosciences and Castle Creek Pharmaceuticals. Harmony Biosciences focuses its research on disorders that involve the central nervous system like cataplexy and narcolepsy. While Castle Creek Pharmaceuticals focus on rare genetic dermatology conditions. The mission of Paragon Biosciences headed by Jeff Aronin is to build biotechnology companies that are innovative and aim in creating medicine for patients across the globe. The focus of his team in Paragon Biosciences on patients and science has led them to create 13 new drugs that are all approved for use.

Paragon Biosciences first identifies the diseases, which have the highest requirement for treatment. The team then studies the disease and the conditions and tries to come up with a better solution to solve the problem (https://www.dailyforexreport.com/jeff-aronins-company-paragon-biosciences-became-investment-incubator/). Afterward, they identify the science that could yield novel treatment, and then they build companies that can help with their research.